Mobile

A 16 week randomised, open labelled, 3-armed, treat-to-target, parallel group trial comparing SIBA (D) once daily + NovoRapid®, SIBA (E) once daily + NovoRapid® and insulin glargine once daily + NovoR...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-002474-60

A 16 week randomised, open labelled, 3-armed, treat-to-target, parallel group trial comparing SIBA (D) once daily + NovoRapid®, SIBA (E) once daily + NovoRapid® and insulin glargine once daily + NovoRapid®, all in a basal/bolus regimen in subjects with type 1 diabetes

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess glucose control with respect to HbA1c after 16 weeks of treatment with SIBA (D) QD + NovoRapid® or SIBA (E) QD + NovoRapid® compared with that of insulin glargine QD + NovoRapid®, all in a basal/bolus regimen, in subjects with type 1 diabetes.

Critère d'inclusion

  • Type 1 Diabetes

Liens